Articles with public access mandates - HW ReesinkLearn more
Not available anywhere: 1
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
CM Lange, S Susser, E Herrmann, U Karey, TL Kieffer, AD Kwong, ...
Scandinavian journal of gastroenterology 46 (11), 1362-1368, 2011
Mandates: German Research Foundation
Available somewhere: 20
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017
Mandates: UK Medical Research Council
Response-guided telaprevir combination treatment for hepatitis C virus infection
KE Sherman, SL Flamm, NH Afdhal, DR Nelson, MS Sulkowski, ...
New England Journal of Medicine 365 (11), 1014-1024, 2011
Mandates: US National Institutes of Health
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
C Sarrazin, TL Kieffer, D Bartels, B Hanzelka, U Müh, M Welker, ...
Gastroenterology 132 (5), 1767-1777, 2007
Mandates: German Research Foundation
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ...
Journal of viral hepatitis 21, 34-59, 2014
Mandates: National Institute for Health Research, UK
Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients
TL Kieffer, C Sarrazin, JS Miller, MW Welker, N Forestier, HW Reesink, ...
Hepatology 46 (3), 631-639, 2007
Mandates: German Research Foundation
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009
WK Roth, MP Busch, A Schuller, S Ismay, A Cheng, CR Seed, ...
Vox Sanguinis 102 (1), 82-90, 2012
Mandates: US National Institutes of Health
Neonatal transfusions
HV New, SJ Stanworth, CP Engelfriet, HW Reesink, ZK McQuilten, ...
Vox Sanguinis: 96 (1), 62, 2009
Mandates: US National Institutes of Health
Rapid decrease of wild-type hepatitis C virus on telaprevir treatment
BS Adiwijaya, B Hare, PR Caron, JCR Randle, AU Neumann, ...
Antiviral therapy 14 (4), 591-595, 2009
Mandates: German Research Foundation
Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101
F Stelma, MH van der Ree, MJ Sinnige, A Brown, L Swadling, ...
Hepatology 66 (1), 57-68, 2017
Mandates: US National Institutes of Health, UK Medical Research Council, National …
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061
E Herrmann, S Zeuzem, C Sarrazin, H Hinrichsen, Y Benhamou, ...
Antiviral therapy 11 (3), 371-376, 2006
Mandates: German Research Foundation
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study
R Erken, P Andre, E Roy, N Kootstra, N Barzic, H Girma, C Laveille, ...
Journal of viral hepatitis 28 (12), 1690-1698, 2021
Mandates: Agence Nationale de la Recherche
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels
L Jansen, A de Niet, F Stelma, EPA van Iperen, KA van Dort, ...
Journal of Hepatology 61 (4), 730-737, 2014
Mandates: US National Institutes of Health
Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B
R Erken, V Loukachov, K van Dort, A van den Hurk, RB Takkenberg, ...
Hepatology 76 (1), 196-206, 2022
Mandates: Netherlands Organisation for Scientific Research
An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B
L Jansen, A de Niet, Z Makowska, MT Dill, KA van Dort, V Terpstra, ...
Liver International 35 (7), 1824-1832, 2015
Mandates: Swiss National Science Foundation
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
MH van der Ree, F Stelma, SB Willemse, A Brown, L Swadling, ...
Antiviral Research 146, 139-145, 2017
Mandates: US National Institutes of Health, UK Medical Research Council, National …
Biobanks of blood from donors and recipients of blood products
HW Reesink, CP Engelfriet, CA Hyland, P Coghlan, B Tait, M Wsolak, ...
Vox sanguinis 94 (3), 242-260, 2008
Mandates: US National Institutes of Health
Identification of a novel HBV encoded miRNA using next generation sequencing
V Loukachov, KA van Dort, L Jansen, HW Reesink, NA Kootstra
Viruses 14 (6), 1223, 2022
Mandates: Netherlands Organisation for Scientific Research
Identification of liver and plasma microRNAs in chronic hepatitis B virus infection
VV Loukachov, KA van Dort, I Maurer, RB Takkenberg, A de Niet, ...
Frontiers in cellular and infection microbiology 12, 790964, 2022
Mandates: Netherlands Organisation for Scientific Research
A single dose of anti-miR-122, RG-101, in CHC patients results in NK cell normalization with no effect on HCV-specific CD8+ T cell function
F Stelma, MH van der Ree, MJ Sinnige, A Brown, L Swadling, ...
Hepatology (Baltimore, Md.) 66 (1), 57, 2017
Mandates: US National Institutes of Health, UK Medical Research Council, National …
Publication and funding information is determined automatically by a computer program